Literature DB >> 33077516

Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions.

Anna S Tocheva1, Michael Peled2, Marianne Strazza3, Kieran R Adam3, Shalom Lerrer3, Shruti Nayak4, Inbar Azoulay-Alfaguter5, Connor J R Foster5, Elliot A Philips6, Benjamin G Neel5, Beatrix Ueberheide4, Adam Mor7.   

Abstract

Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell-mediated anti-tumor responses. Consequently, therapeutic blockade of PD-1 enhances T cell-mediated anti-tumor immunity, but many patients do not respond and a significant proportion develop inflammatory toxicities. To improve anti-cancer therapy, it is critical to reveal the mechanisms by which PD-1 regulates T cell responses. We performed global quantitative phosphoproteomic interrogation of PD-1 signaling in T cells. By complementing our analysis with functional validation assays, we show that PD-1 targets tyrosine phosphosites that mediate proximal T cell receptor signaling, cytoskeletal organization, and immune synapse formation. PD-1 ligation also led to differential phosphorylation of serine and threonine sites within proteins regulating T cell activation, gene expression, and protein translation. In silico predictions revealed that kinase/substrate relationships engaged downstream of PD-1 ligation. These insights uncover the phosphoproteomic landscape of PD-1-triggered pathways and reveal novel PD-1 substrates that modulate diverse T cell functions and may serve as future therapeutic targets. These data are a useful resource in the design of future PD-1-targeting therapeutic approaches.
© 2020 Tocheva et al.

Entities:  

Keywords:  T cell; T cell receptor (TCR); cell signaling; immunology; immunotherapy; inhibition mechanism; kinase-substrate relationships; mass spectrometry; phosphoproteomics; programmed cell death ligand 2 (PD-L2); programmed cell death protein 1 (PD-1); signaling networks

Mesh:

Substances:

Year:  2020        PMID: 33077516      PMCID: PMC7939457          DOI: 10.1074/jbc.RA120.014745

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Jurkat T cells and development of the T-cell receptor signalling paradigm.

Authors:  Robert T Abraham; Arthur Weiss
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

2.  The coreceptor programmed death 1 inhibits T-cell adhesion by regulating Rap1.

Authors:  Inbar Azoulay-Alfaguter; Marianne Strazza; Ariel Pedoeem; Adam Mor
Journal:  J Allergy Clin Immunol       Date:  2014-09-18       Impact factor: 10.793

3.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

Review 4.  SLAM family receptors and SAP adaptors in immunity.

Authors:  Jennifer L Cannons; Stuart G Tangye; Pamela L Schwartzberg
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

Authors:  Nikolaos Patsoukis; Lequn Li; Duygu Sari; Victoria Petkova; Vassiliki A Boussiotis
Journal:  Mol Cell Biol       Date:  2013-06-03       Impact factor: 4.272

6.  GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy.

Authors:  Yu Xue; Jian Ren; Xinjiao Gao; Changjiang Jin; Longping Wen; Xuebiao Yao
Journal:  Mol Cell Proteomics       Date:  2008-05-06       Impact factor: 5.911

7.  The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.

Authors:  Elliot A Philips; Antonio Garcia-España; Anna S Tocheva; Ian M Ahearn; Kieran R Adam; Ruimin Pan; Adam Mor; Xiang-Peng Kong
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

8.  Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome.

Authors:  Haiyan Tan; Zhiping Wu; Hong Wang; Bing Bai; Yuxin Li; Xusheng Wang; Bo Zhai; Thomas G Beach; Junmin Peng
Journal:  Proteomics       Date:  2014-12-15       Impact factor: 3.984

Review 9.  Inhibitory Receptors Beyond T Cell Exhaustion.

Authors:  Silvia A Fuertes Marraco; Natalie J Neubert; Grégory Verdeil; Daniel E Speiser
Journal:  Front Immunol       Date:  2015-06-26       Impact factor: 7.561

10.  Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.

Authors:  Alison Taylor; Christopher E Rudd
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

View more
  8 in total

Review 1.  A comprehensive review of SHP2 and its role in cancer.

Authors:  Moges Dessale Asmamaw; Xiao-Jing Shi; Li-Rong Zhang; Hong-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2022-09-06       Impact factor: 7.051

2.  Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells.

Authors:  Marianne Strazza; Inbar Azoulay-Alfaguter; Michael Peled; Kieran Adam; Adam Mor
Journal:  Commun Biol       Date:  2021-06-03

3.  SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.

Authors:  Marianne Strazza; Kieran Adam; Shalom Lerrer; Johanna Straube; Sabina Sandigursky; Beatrix Ueberheide; Adam Mor
Journal:  Inflammation       Date:  2021-02-24       Impact factor: 4.657

4.  VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses.

Authors:  Michael Peled; Anna S Tocheva; Kieran Adam; Adam Mor
Journal:  Immunol Lett       Date:  2021-03-16       Impact factor: 4.230

Review 5.  Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.

Authors:  Nagaja Capitani; Laura Patrussi; Cosima T Baldari
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 6.  Immune Checkpoint Receptors Signaling in T Cells.

Authors:  Gianluca Baldanzi
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

Review 7.  Combination Approaches to Target PD-1 Signaling in Cancer.

Authors:  Emily K Moore; Marianne Strazza; Adam Mor
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

Review 8.  Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.

Authors:  Adam Mor; Marianne Strazza
Journal:  Front Cell Dev Biol       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.